-
Professor Minghui Duan: The Central Role of Genetic Testing in Hematologic Malignancies and Its Guidance for Personalized Therapy
From July 11 to 13, 2025, the 9th Annual Hematologic Oncology Congress of the Chinese Society of Clinical Oncology (CSCO) was held in Harbin. The event brought together top experts from China and abroad to discuss key issues in hematologic malignancies, including leukemia, lymphoma, and multiple myeloma. Topics spanned basic research, innovative drug development, precision…
-
Professor Yu Zhang: Optimizing the Diagnostic and Treatment Pathway for AML – The Southern Hospital Experience | 9th CSCO Hematologic Oncology Congres
From July 11 to 13, 2025, the 9th Annual Hematologic Oncology Congress hosted by the Chinese Society of Clinical Oncology (CSCO) took place in Harbin. The conference brought together leading experts from China and abroad to discuss key topics in hematologic malignancies, including leukemia, lymphoma, and multiple myeloma. Topics ranged from basic research and innovative…
-
Prof. Masatoshi Kudo on Comparing IO Regimens in HCC
At ESMO, Professor Masatoshi Kudo from Kindai University shared results from a matching-adjusted indirect comparison of nivolumab + ipilimumab (CheckMate 9DW) versus durvalumab + tremelimumab (HIMALAYA) and atezolizumab + bevacizumab…
-
Prof. Markus Moehler on RATIONAL 305 and Global Progress in Gastric Cancer
At ESMO, Professor Markus Moehler, Head of the GI Oncology Unit at the University Medical Center Mainz, shared findings from the phase III RATIONAL 305 trial, which evaluated tislelizumab plus…
-
China-Germany-Japan Roundtable | Insights on the TALENT Study in HCC
At a recent international roundtable, experts from China, Germany, and Japan shared their perspectives on the TALENT study, which evaluated the combination of TACE with atezolizumab and bevacizumab for patients…
-
ESMO GI | A China-Europe Dialogue with Professor Gang Jin & Professor Teresa Macarulla on PANOVA-3: Tumor-Treating Fields Help Patients with Locally Advanced Pancreatic Cancer Live Longer—and Better
Oncology Frontier invited Professor Gang Jin, principal investigator of PANOVA-3 in China and Chair of the Department of Hepatobiliary and Pancreatic Surgery at Changhai Hospital, Naval Medical University, and Professor…
-
Professor Xiaojian Qin: Enabling Prostate Cancer Patients to Live Longer—and Better—with Simpler, More Confident Care
The 2025 Pujiang Prostate Cancer Academic Congress was held from June 27–28 in Shanghai, in collaboration with the Annual Meeting of the CSCO Prostate Cancer Committee (CSCO-PC), the Prostate Cancer Conference of the CACA Genitourinary Oncology Committee (CACA-GO), and the Chinese Prostate Cancer Consortium (CPCC) Annual Meeting. Centered around the theme “Global Wisdom, Chinese Practice,…
-
Professor Bo Dai: Targeting PSMA—How Novel Radioligand Therapies Are Reshaping the Treatment Landscape for Prostate Cancer
01 Oncology Frontier – Urology Frontier: Could you share the current clinical application and research progress of PSMA-targeted radioligand therapy in prostate cancer? Professor Bo Dai: PSMA-targeted radioligand therapy has…
Connecting Medical Expertise through Media